NCT02339922 2026-03-05
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT03817320 2025-06-17
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Active not recruiting
NCT02547662 2023-10-30
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Mayo Clinic
Phase 2 Completed
NCT04079738 2023-09-13
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT02169791 2021-09-02
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Northside Hospital, Inc.
Phase 2 Completed
NCT01887587 2020-01-22
Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
Medical College of Wisconsin
Phase 1 Terminated
NCT02030405 2019-04-05
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Phase 2 Terminated
NCT02302846 2018-10-03
Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01912222 2016-06-02
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
Millennium Pharmaceuticals, Inc.
Phase 1 Completed